Edition:
United Kingdom

VistaGen Therapeutics Inc (VTGN.OQ)

VTGN.OQ on NASDAQ Stock Exchange Capital Market

1.17USD
12 Dec 2017
Change (% chg)

$-0.05 (-4.10%)
Prev Close
$1.22
Open
$1.23
Day's High
$1.23
Day's Low
$1.13
Volume
222,921
Avg. Vol
162,639
52-wk High
$3.91
52-wk Low
$0.69

Select another date:

Thu, Nov 9 2017

BRIEF-Vistagen Therapeutics posts Q2 loss of $0.53 per share

* Vistagen therapeutics reports second fiscal quarter 2018 financial results and provides business update

BRIEF-Vistagen Therapeutics receives European patent for AV-101 for treatment of depression

* Vistagen Therapeutics receives European patent for AV-101 for treatment of depression Source text for Eikon: Further company coverage:

BRIEF-Vistagen gets FDA authorization to initiate phase 2 study for major depressive disorder

* Vistagen announces fda authorization to initiate phase 2 study of av-101 for major depressive disorder Source text for Eikon: Further company coverage:

BRIEF-VistaGen Therapeutics files for offering of up to $23 mln of common stock

* VistaGen Therapeutics Inc files for offering of up to $23 million of common stock – SEC filing‍​ Source text: [http://bit.ly/2zkDNCU] Further company coverage:

BRIEF-Vistagen receives notice of allowance from U.S. Patent And Trademark Office

* Vistagen receives notice of allowance from U.S. Patent and Trademark office for U.S. Patent regarding methods of production for av-101 Source text for Eikon: Further company coverage:

BRIEF-Vistagen to buy up to 1.9 mln shares of common stock at $1.75 per share

* Vistagen announces pricing of underwritten offering of common stock and warrants to purchase common stock

BRIEF-Vistagen Therapeutics appoints Dr. Mark Wallace to clinical advisory board

* Vistagen Therapeutics appoints Dr. Mark Wallace to clinical advisory board to advance AV-101 as a potential non-opioid treatment for neuropathic pain Source text for Eikon: Further company coverage:

Select another date: